{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:12:49Z","timestamp":1778721169456,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41375-019-0592-8","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T12:02:51Z","timestamp":1570449771000},"page":"2555-2562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["What is new in the treatment of Waldenstrom macroglobulinemia?"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,7]]},"reference":[{"key":"592_CR1","unstructured":"Swerdlow SH, Cook JR, Sohani AR, Pileri SA, Harris NL, Jaffe ES, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 232\u20135."},{"key":"592_CR2","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2012;367:826\u201333.","journal-title":"N Engl J Med"},{"key":"592_CR3","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/leu.2013.62","volume":"27","author":"C Jimenez","year":"2013","unstructured":"Jimenez C, Sebastian E, Chillon MC, Giraldo P, Mariano Hernandez J, Escalante F, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom\u2019s macroglobulinemia. Leukemia. 2013;27:1722\u20138.","journal-title":"Leukemia."},{"key":"592_CR4","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","volume":"121","author":"S Poulain","year":"2013","unstructured":"Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121:4504\u201311.","journal-title":"Blood."},{"key":"592_CR5","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","volume":"121","author":"M Varettoni","year":"2013","unstructured":"Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121:2522\u20138.","journal-title":"Blood."},{"key":"592_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bjh.15049","volume":"180","author":"SP Treon","year":"2018","unstructured":"Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, et al. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180:374\u201380.","journal-title":"Br J Haematol"},{"key":"592_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123:1637\u201346.","journal-title":"Blood."},{"key":"592_CR8","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","volume":"123","author":"AM Roccaro","year":"2014","unstructured":"Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, et al. C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123:4120\u201331.","journal-title":"Blood."},{"key":"592_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bjh.13361","volume":"169","author":"J Schmidt","year":"2015","unstructured":"Schmidt J, Federmann B, Schindler N, Steinhilber J, Bonzheim I, Fend F, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;169:795\u2013803.","journal-title":"Br J Haematol"},{"key":"592_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","volume":"22","author":"S Poulain","year":"2016","unstructured":"Poulain S, Roumier C, Venet-Caillault A, Figeac M, Herbaux C, Marot G, et al. Genomic landscape of CXCR4 mutations in waldenstrom macroglobulinemia. Clin Cancer Res. 2016;22:1480\u20138.","journal-title":"Clin Cancer Res."},{"key":"592_CR11","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP. CXCR4 mutations affect presentation and outcomes in patients with Waldenstrom macroglobulinemia: a systematic review. Exp Rev Hematol. 2019:1\u20139.","DOI":"10.1080\/17474086.2019.1649132"},{"key":"592_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1634\/theoncologist.2016-0126","volume":"21","author":"AJ Olszewski","year":"2016","unstructured":"Olszewski AJ, Treon SP, Castillo JJ. Evolution of management and outcomes in Waldenstrom macroglobulinemia: a population-based analysis. Oncologist. 2016;21:1377\u201386.","journal-title":"Oncologist."},{"key":"592_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","volume":"24","author":"SP Treon","year":"2001","unstructured":"Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom\u2019s macroglobulinemia. J Immunother. 2001;24:272\u20139.","journal-title":"J Immunother."},{"key":"592_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/annonc\/mdi022","volume":"16","author":"SP Treon","year":"2005","unstructured":"Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, et al. Extended rituximab therapy in Waldenstrom\u2019s macroglobulinemia. Ann Oncol. 2005;16:132\u20138.","journal-title":"Ann Oncol."},{"key":"592_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3816\/CLM.2002.n.022","volume":"3","author":"MA Dimopoulos","year":"2002","unstructured":"Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, et al. Extended rituximab therapy for previously untreated patients with Waldenstrom\u2019s macroglobulinemia. Clin Lymphoma. 2002;3:163\u20136.","journal-title":"Clin Lymphoma."},{"key":"592_CR16","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1080\/10428190410001714043","volume":"45","author":"MA Gertz","year":"2004","unstructured":"Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45:2047\u201355.","journal-title":"Leuk Lymphoma."},{"key":"592_CR17","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1002\/cncr.20658","volume":"101","author":"IM Ghobrial","year":"2004","unstructured":"Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, et al. Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101:2593\u20138.","journal-title":"Cancer."},{"key":"592_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","volume":"15","author":"SP Treon","year":"2004","unstructured":"Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom\u2019s macroglobulinemia. Ann Oncol. 2004;15:1481\u20133.","journal-title":"Ann Oncol."},{"key":"592_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/bjh.13794","volume":"174","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Kanan S, Meid K, Manning R, Hunter ZR, Treon SP. Rituximab intolerance in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2016;174:645\u20138.","journal-title":"Br J Haematol"},{"key":"592_CR20","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","volume":"4","author":"RR Furman","year":"2017","unstructured":"Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, et al. Once-weekly ofatumumab in untreated or relapsed Waldenstrom\u2019s macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017;4:e24\u2013e34.","journal-title":"Lancet Haematol."},{"key":"592_CR21","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","volume":"25","author":"MA Dimopoulos","year":"2007","unstructured":"Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344\u20139.","journal-title":"J Clin Oncol."},{"key":"592_CR22","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","volume":"126","author":"E Kastritis","year":"2015","unstructured":"Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126:1392\u20134.","journal-title":"Blood."},{"key":"592_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet."},{"key":"592_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.15148","volume":"181","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia. Br J Haematol. 2018;181:77\u201385.","journal-title":"Br J Haematol"},{"key":"592_CR25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","volume":"97","author":"J Paludo","year":"2018","unstructured":"Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018;97:1417\u201325.","journal-title":"Ann Hematol."},{"key":"592_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/bjh.14667","volume":"178","author":"P Martin","year":"2017","unstructured":"Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017;178:250\u20136.","journal-title":"Br J Haematol"},{"key":"592_CR27","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","volume":"122","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122:3276\u201382.","journal-title":"Blood."},{"key":"592_CR28","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","volume":"28","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28:1422\u20138.","journal-title":"J Clin Oncol."},{"key":"592_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ajh.21788","volume":"85","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol. 2010;85:670\u20134.","journal-title":"Am J Hematol."},{"key":"592_CR30","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830\u20135.","journal-title":"J Clin Oncol."},{"key":"592_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","volume":"124","author":"SP Treon","year":"2014","unstructured":"Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom\u2019s macroglobulinemia. Blood. 2014;124:503\u201310.","journal-title":"Blood."},{"key":"592_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431\u201340.","journal-title":"Lancet Oncol"},{"key":"592_CR33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2015;372:1430\u201340.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"592_CR34","first-page":"2766","volume":"130","author":"SP Treon","year":"2017","unstructured":"Treon SP, Meid K, Gustine J, Bantilan KS, Dubeau T, Severns P, et al. Long-term follow-up of previously treated patients who received ibrutinib for symptomatic Waldenstrom\u2019s macroglobulinemia: update of pivotal clinical trial. Blood. 2017;130(Suppl 1):2766.","journal-title":"Blood."},{"key":"592_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241\u201350.","journal-title":"Lancet Oncol"},{"key":"592_CR36","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","volume":"36","author":"SP Treon","year":"2018","unstructured":"Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2018;36:2755\u201361.","journal-title":"J Clin Oncol."},{"key":"592_CR37","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","volume":"100","author":"AH Lipsky","year":"2015","unstructured":"Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100:1571\u20138.","journal-title":"Haematologica."},{"key":"592_CR38","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829\u201330.","journal-title":"Blood."},{"key":"592_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","volume":"175","author":"L Pretorius","year":"2009","unstructured":"Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175:998\u20131009.","journal-title":"Am J Pathol."},{"key":"592_CR40","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4:1491\u20131500.","journal-title":"JACC Clin Electrophysiol."},{"key":"592_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138\u201340.","journal-title":"Blood."},{"key":"592_CR42","doi-asserted-by":"publisher","first-page":"E312","DOI":"10.1002\/ajh.24366","volume":"91","author":"JN Gustine","year":"2016","unstructured":"Gustine JN, Meid K, Dubeau TE, Treon SP, Castillo JJ. Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia. Am J Hematol. 2016;91:E312\u2013E313.","journal-title":"Am J Hematol."},{"issue":"S2","key":"592_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hon.141_2629","volume":"37","author":"SP Treon","year":"2019","unstructured":"Treon SP, Meid K, Gustine J, Yang G, Xu L, Patterson CJ, et al. Ibrutinib monotherapy produces long-term disease control in previously treated Waldenstrom\u2019s macroglobulinemia. final report of the pivotal trial (NCT01614821). Hematol Oncol. 2019;37(S2):184\u20135.","journal-title":"Hematol Oncol."},{"key":"592_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","volume":"72","author":"A Guha","year":"2018","unstructured":"Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72:697\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"592_CR45","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","volume":"129","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129:2581\u20134.","journal-title":"Blood."},{"key":"592_CR46","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2018;378:2399\u2013410.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"592_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1182\/blood-2018-99-111178","volume":"132","author":"C Buske","year":"2018","unstructured":"Buske C, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib treatment in Waldenstr\u00f6m\u2019s macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. Blood. 2018;132(Suppl 1):149\u2013149.","journal-title":"Blood."},{"key":"592_CR48","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1182\/blood-2016-01-695098","volume":"127","author":"G Yang","year":"2016","unstructured":"Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127:3237\u201352.","journal-title":"Blood."},{"key":"592_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharm Exp Ther. 2017;363:240\u201352.","journal-title":"J Pharm Exp Ther"},{"key":"592_CR50","doi-asserted-by":"crossref","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of Zanubrutinib (BGB-3111), a novel, potent and selective covalent inhibitor of bruton\u2019s tyrosine kinase. J Med Chem. 2019;62:7923-7940.","DOI":"10.1021\/acs.jmedchem.9b00687"},{"key":"592_CR51","unstructured":"Owen R, McCarthy H, Rule S, D\u2019Sa S, Thomas S, Forconi F, et al. Acalabrutinib in patients with Waldenstr\u00f6m macroglobulinemia.\u00a0HemaSphere. 2018;2:375-376."},{"key":"592_CR52","doi-asserted-by":"crossref","unstructured":"Trotman J, Opat S, Marlton P, Gottlieb D, Simpson D, Cull G, et al. Updated safety and efficacy data in a phase 1\/2 trial of patients with Waldenstr\u00f6m macroglobulinaemia (WM) treated with the bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111).\u00a0HemaSphere. 2019;3:192-193.","DOI":"10.1097\/01.HS9.0000560224.52872.d6"},{"key":"592_CR53","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Opat S, Lee HP, Cull G, D\u2019Sa S, Owen R, et al. Major responses in MYD88 wildtype (MYD88WT) Waldenstr\u00f6m macroglobulinemia (WM) patients treated with bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111). HemaSphere. 2019;3:196.","DOI":"10.1097\/01.HS9.0000560248.83366.72"},{"key":"592_CR54","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17:5311\u201321.","journal-title":"Clin Cancer Res."},{"key":"592_CR55","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1021\/jm801329v","volume":"52","author":"HJ Zhou","year":"2009","unstructured":"Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009;52:3028\u201338.","journal-title":"J Med Chem"},{"key":"592_CR56","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","volume":"24","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstrom macroglobulinemia. Clin Cancer Res. 2018;24:3247\u201352.","journal-title":"Clin Cancer Res."},{"key":"592_CR57","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, et al. A phase Ib\/II study of oprozomib in patients with advanced multiple myeloma and Waldenstrom macroglobulinemia. Clin Cancer Res. 2019.\u00a025:4907-4916.","DOI":"10.1158\/1078-0432.CCR-18-3728"},{"key":"592_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/sonc.2003.50074","volume":"30","author":"JF San Miguel","year":"2003","unstructured":"San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML, et al. Immunophenotypic analysis of Waldenstrom\u2019s macroglobulinemia. Semin Oncol. 2003;30:187\u201395.","journal-title":"Semin Oncol."},{"key":"592_CR59","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2016-03-708263","volume":"128","author":"ZR Hunter","year":"2016","unstructured":"Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X, et al. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstrom macroglobulinemia. Blood. 2016;128:827\u201338.","journal-title":"Blood."},{"key":"592_CR60","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35:826\u201333.","journal-title":"J Clin Oncol."},{"key":"592_CR61","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1182\/blood-2018-99-112325","volume":"132","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau T, Keezer A, Allan J, et al. Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Blood. 2018;132:2888.","journal-title":"Blood."},{"key":"592_CR62","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008\u201318.","journal-title":"N Engl J Med"},{"key":"592_CR63","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1080\/10428194.2016.1222380","volume":"58","author":"JJ Castillo","year":"2017","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau T, Yang G, Xu L, et al. Idelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017;58:1002\u20134.","journal-title":"Leuk Lymphoma."},{"key":"592_CR64","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Chronic lymphocytic leukemia\/small lymphocytic lymphoma. Version 5.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf . Accessed 11 Aug 2019."},{"key":"592_CR65","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/bjh.15515","volume":"183","author":"A Paulus","year":"2018","unstructured":"Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, et al. Targeting CD38 with daratumumab is lethal to Waldenstrom macroglobulinaemia cells. Br J Haematol. 2018;183:196\u2013211.","journal-title":"Br J Haematol"},{"key":"592_CR66","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood.V126.23.4004.4004","volume":"126","author":"G Yang","year":"2015","unstructured":"Yang G, Liu X, Chen J, Xu L, Tsakmaklis N, Chen J, et al. Targeting IRAK1\/IRAK4 signaling in Waldenstrom\u2019s macroglobulinemia. Blood. 2015;126:4004.","journal-title":"Blood."},{"key":"592_CR67","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by DASATINIB: possible combinations in solid tumors. Clin Cancer Res. 2011;17:5546\u201352.","journal-title":"Clin Cancer Res."},{"key":"592_CR68","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","volume":"107","author":"SF Elsawa","year":"2006","unstructured":"Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood. 2006;107:2882\u20138.","journal-title":"Blood."},{"key":"592_CR69","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689\u201394.","journal-title":"Blood."},{"key":"592_CR70","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/leu.2017.219","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:2278.","journal-title":"Leukemia."},{"key":"592_CR71","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"592_CR72","doi-asserted-by":"publisher","unstructured":"Shancer Z, Liu XF, Nagata S, Zhou Q, Bera TK, Pastan I. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. Proc Natl Acad Sci USA. 2019.\u00a0 https:\/\/doi.org\/10.1073\/pnas.1821733116 . [Epub ahead of print]","DOI":"10.1073\/pnas.1821733116"},{"key":"592_CR73","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"592_CR74","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"592_CR75","doi-asserted-by":"publisher","first-page":"suppl: 7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J Clin Oncol. 2018;36:suppl: 7505.","journal-title":"J Clin Oncol."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0592-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:16Z","timestamp":1684618696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0592-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,7]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0592-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,7]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JJC received honoraria and\/or research funds from Abbvie, Beigene, Janssen, Millennium, Pharmacyclics, and TG Therapeutics. SPT received honoraria and\/or research funds from Bristol-Meyer-Squibb and Pharmacyclics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}